Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study – Merck.com & more related News Here
Merck and Gilead provide update on Phase 3 KEYNOTE-D46/EVOKE-03 studymerck.com Gilead and Merck announced positive topline results from two Phase 3 studies evaluating islatravir/lencapavir, a once-weekly oral HIV treatmentbusiness wire Gilead’s lung cancer bid for Trodelvy hit, but HIV studies give better newsFirstward Pharma Will an HIV win and a lung cancer loss in trials…
